Juvenescence is a developer of therapeutics designed to increase healthy human longevity. They are building a portfolio of therapeutic assets targeting ageing, regeneration and the diseases of aging. Juvenescence and its portfolio companies use AI and machine learning techniques to discover and develop new drugs. They have established strong partnerships with numerous universities and institutions, most notably The Buck Institute for Research on Ageing.
With its portfolio of medical innovators, Juvenessence’s technologies have the impact both the medical and economics of longevity and ageing.